Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Scientific Contributions

Effect of Continuous Positive Airway Pressure on Blood Pressure

A Placebo Trial

Joel E. Dimsdale, Jose S. Loredo, Judi Profant
Download PDF
https://doi.org/10.1161/01.HYP.35.1.144
Hypertension. 2000;35:144-147
Originally published January 1, 2000
Joel E. Dimsdale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose S. Loredo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judi Profant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—This study examined the effect of continuous positive airway pressure (CPAP) treatment on blood pressure in patients with obstructive sleep apnea. Thirty-nine patients with sleep apnea were studied. Ambulatory blood pressure monitoring was obtained before and after patients were randomized to receive either 1 week of CPAP or placebo CPAP (CPAP administered at ineffective pressure). Blood pressure was examined over daytime hours (6 am to 10 pm) and during nighttime hours (10 pm to 6 am). Daytime mean arterial blood pressure decreased significantly but equally in both the active treatment group and the placebo treatment group (P=0.001). Nighttime mean arterial pressure levels decreased to a much greater extent over time in the patients who received active CPAP treatment (P=0.032). CPAP does appear to decrease nighttime blood pressure. However, the decrease in daytime blood pressure may reflect a nonspecific response (ie, placebo), since both the active treatment group and the placebo treatment group developed comparable decreases in blood pressure.

  • apnea
  • blood pressure
  • blood pressure monitoring, ambulatory
  • placebo effect

Obstructive sleep apnea (OSA) is commonly associated with increased blood pressure (BP).1 2 3 4 Treatments for OSA are multiple, but, after weight loss, the most commonly used treatment is nocturnal continuous positive airway pressure (CPAP). The great majority of OSA patients can have their apnea successfully treated with this methodology.5

Because of the comorbidity of hypertension and OSA, many investigators have examined how CPAP affects BP levels.6 7 8 9 10 11 12 13 14 15 16 17 18 19 Table 1⇓ summarizes these endeavors. As the table suggests, many of the studies report a beneficial effect of CPAP on BP. The studies suggest that CPAP acutely decreases nighttime BP in hypertensive OSA patients but not in normotensive patients and that longer-term use of CPAP decreases both nocturnal and diurnal BP. However, certain design aspects are striking. The studies generally have a small sample size (average of 14 patients per study), and most of them use neither randomization nor a control group. Most studies combined normotensives and hypertensives, and many hypertensives were studied while they were receiving antihypertensive treatment. Few studies examined patients in the absence of antihypertensive medication. Most studies did not describe how they dealt with data from patients who were noncompliant with the CPAP treatment.

View this table:
  • View inline
  • View popup
Table 1.

Studies of Effect of CPAP on BP

Only half of the studies used ambulatory blood pressure monitoring (ABPM). ABPM techniques acquire a more complete and representative sample of BP readings than would be obtained by casual BP measurement in the physician’s office. In addition, ABPM allows examination of BP patterns in awake and in sleeping patients.

Most notably, only 1 study used a placebo control (an oral placebo) for CPAP, and that study found no effect of CPAP on 24-hour ambulatory BP.8 BP is notoriously influenced by nonspecific effects. The CPAP apparatus itself could be a very powerful stimulus for placebo responses. For this reason, we performed a double-blind placebo trial of CPAP versus placebo CPAP on BP as gauged by ABPM.

Methods

Patients were located by public advertisements and word-of-mouth referral. All patients signed written informed consent approved by the University of California at San Diego Institutional Review Board. Patients were eligible if they were between the ages of 30 and 65 years and were 100% to 170% of ideal body weight as determined by Metropolitan norms.20 Patients were ineligible if they had any major ongoing illness other than sleep apnea and hypertension.

Patients receiving antihypertensive medication had their medication slowly tapered and their BP status confirmed after a 3-week washout. Patients’ BP was screened repeatedly (3 times on 2 occasions) after they had been seated resting for at least 5 minutes. Individuals whose BP was <140/90 mm Hg were considered normotensive. Patients whose BP was >140/90 but <180/110 mm Hg were considered hypertensive and eligible to participate in this protocol.

Sleep was screened at home with a Nightwatch system, and individuals whose respiratory disturbance index (RDI) at home was >20 were considered provisionally to have OSA.

Patients wore a Spacelabs ambulatory blood pressure monitor (model 90207) for a 24-hour period on 3 occasions: before CPAP/placebo CPAP randomization, after 1 day of treatment, and after 7 days of treatment (indicated on graphs as day 0, day 1, and day 7). The cuff was positioned carefully with a “Y” adaptor, and placement was validated against a mercury sphygmomanometer. The cuff position was outlined in ink on the patient’s arm so that the cuff could be repositioned easily if it shifted over the course of the day. BP was programmed to be taken every 15 minutes between 6 am and 10 pm and every 30 minutes between 10 pm and 6 am. Standard criteria for artifact rejection were used in evaluating the BP measures.

Patients were admitted to the University of California at San Diego Clinical Research Center for a confirmatory overnight polysomnography (Nihon Koden, model 4412p). We recorded the following parameters: central and occipital electroencephalogram, bilateral electro-oculogram, submental and tibialis anterior electromyogram, ECG, nasal/oral airflow using thermistor, and respiratory effort using chest and abdominal inductance belts. Oxyhemoglobin saturation was recorded with a pulse oximeter (Biox 3740). Individuals whose RDI was >15 were considered to have OSA. On the next night, patients were randomized to receive either CPAP or placebo CPAP. Patients receiving CPAP underwent standard CPAP titration with the use of a Devilbis CPAP machine and a comfortably fitting mask. Pressure in the mask started at 2 cm H2O and was increased over the night by 2-cm H2O increments until apneic episodes were obliterated or until a pressure of 8 to 10 cm was reached. Further pressure titration was then done in increments of 1 cm H2O on the basis of the presence of apnea, hypopnea, or snoring associated with arousals. The titration was considered ended when most respiratory events were controlled with CPAP while the patient was in the supine position and in the second or third rapid eye movement sleep period or until a pressure of 20 cm had been reached. All patients had their apnea treated within this pressure range.

Individuals randomized to receive placebo CPAP underwent a mock titration night. They wore a special mask that had 5 one-quarter-inch drill holes to create a large leak through the mask. Their CPAP pressure was set at 2 cm H2O and was not advanced. All CPAP units had a hidden compliance clock that allowed measurement of the amount of time the machine was switched on.

One day after CPAP or placebo CPAP treatment was initiated, patients completed a second day of ABPM. They were then discharged from the hospital for 1 week of continuing CPAP or placebo treatment at home. The research staff was in frequent contact with patients to answer questions about mask placement and to encourage compliance with the treatment. After 7 days of home treatment, patients’ ambulatory BP was again studied with the use of the Spacelabs ambulatory monitor.

Data were analyzed with repeated-measures ANOVA with the use of SPSS software. If a significant effect was found for time alone, it would imply that CPAP did not have a specific effect on BP. If there was a significant interaction of time and treatment, it would imply that the group receiving a particular treatment (presumably CPAP) had a differential response to that treatment over time.

Results

Table 2⇓ summarizes the sample characteristics. Thirty-nine individuals were studied. Individuals randomized to the 2 treatments were comparable in age, pretreatment RDI, and screened BP; however, patients randomized to receive CPAP were heavier (P<0.05). The mean mask pressure required among the CPAP group was 10.1 cm H2O; placebo CPAP patients all received CPAP at a pressure of 2 cm H2O administered through a mask with numerous air holes to produce a large air leak. Both patient groups complied equivalently with the CPAP treatment over the 1-week interval of home treatment (>5 hours per night for each group). Patients receiving CPAP demonstrated a significantly greater drop in RDI than was observed in patients assigned to the placebo CPAP group (time×CPAP interaction, P=0.001) (Table 2⇓).

View this table:
  • View inline
  • View popup
Table 2.

Patient Sample Characteristics

ABPM revealed a main effect for time on daytime mean arterial pressure (F=7.96, df=2, P=0.001) (Figure 1⇓). The daytime BP of both groups declined equivalently over the 1-week trial (ie, there was no effect specific to the CPAP group per se). At nighttime, there was a time-by-group interaction such that the BP of patients receiving CPAP fell considerably more over time than the BP of patients assigned to placebo CPAP (F=3.62, df=2, P=0.032) (Figure 2⇓).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Effect of CPAP on daytime mean arterial pressure. Mean arterial pressure was measured during daytime with ABPM before treatment (day 0), after 1 day, and after 7 days of treatment with either CPAP or placebo CPAP. There was a nonspecific time effect for lowering BP across both treatments (P=0.001).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Effect of CPAP on nocturnal mean arterial pressure. Mean arterial pressure was measured during nighttime with ABPM before treatment (day 0), after 1 day, and after 7 days of treatment with either CPAP or placebo CPAP. CPAP leads to a specific time-by-treatment effect on blood pressure (P=0.032).

Discussion

The treatment of sleep apnea is rapidly evolving. Medications have had limited value compared with weight loss, various surgical procedures, and CPAP.21 For the vast majority of patients, CPAP is an effective treatment of the apnea per se if the patient complies with the treatment. Our results suggest, however, that the effects of CPAP on BP are not so straightforward.

Had we not administered a placebo version of CPAP, we would have concluded that CPAP has a robust BP-lowering effect. That conclusion is not strongly supported by our data. Whereas CPAP lowered daytime mean arterial pressure, so did placebo CPAP. There is very little acclimatization effect to wearing an ABPM cuff22 ; that is, BP does not noticeably fall on a second 24-hour ABPM study. We interpret the uniform decrease of BP in our study to a nonspecific effect of treatment, ie, a placebo effect. Patients were observed closely by our research staff, and all patients used impressive-looking CPAP machinery while sleeping. The combination of professional attention and expectations from the machinery may well have lowered daytime BP. In this sense, the placebo effects of CPAP on BP join a long list of other treatments that have beneficial although nonspecific effects.

However, it is not accurate to attribute all of the effects of CPAP on BP to a placebo effect. We did observe a differential effect of CPAP on nocturnal BP. In the absence of the waking conscious awareness of the treatment (in which treatment had a beneficial effect on both groups), only the patients receiving effective CPAP lowered their nighttime BP.

We specifically examined weight and hypertension to assess whether our findings would materially change after controlling for these variables. Because of the difference in weight between the treatment and placebo groups, we repeated the analyses using body mass index as a covariate. The study still failed to reveal a specific time-by-treatment effect on BP lowering after controlling for BMI. We also reanalyzed the data using screening blood pressure (hypertension versus normotension) as a grouping factor to determine whether hypertension affected the response of BP to CPAP. We found no evidence to suggest that CPAP had a greater BP-lowering effect in hypertensive patients.

The study has a number of limitations. We examined CPAP effects for only a 1-week interval because we were uneasy about imposing a lengthy placebo CPAP treatment on patients who had OSA. It is possible that the BP-lowering effects of CPAP become even more apparent over a longer time interval; indeed, Figure 1⇑ suggests this, but we have no data beyond a 1-week trial. Our patients all had substantial levels of apnea (average RDI was 48.1), but in other ways they were relatively healthy. We excluded patients with other major illnesses requiring treatment, such as those with congestive heart failure, a history of myocardial infarction, or morbid obesity. Perhaps such latter patients may obtain substantially greater benefits with CPAP treatment.

Nonetheless, our study provides a cautionary note, demonstrating the value and importance of a placebo arm in medical research. Even though CPAP is effective in treating apnea, whether it benefits daytime BP is not clear.

Acknowledgments

This study was supported by grants HL-44915 and RR-00827 from the National Institutes of Health.

  • Received April 7, 1999.
  • Revision received May 12, 1999.
  • Accepted September 8, 1999.

References

  1. ↵
    Brooks D, Horner R, Kozar L, Render-Teixeira C, Phillipson E. Obstructive sleep apnea as a cause of systemic hypertension: evidence from a canine model. J Clin Invest. 1997;99:106–109.
    OpenUrlCrossRefPubMed
  2. ↵
    Guilleminault C, Robinson A. Sleep-disordered breathing and hypertension: past lessons, future directions. Sleep. 1997;20:806–811.
    OpenUrlPubMed
  3. ↵
    Worsnop C, Naughton M, Barter C, Morgan T, Anderson A, Pierce R. The prevalence of obstructive sleep apnea in hypertensives. Am J Respir Crit Care Med. 1998;157:111–115.
    OpenUrlPubMed
  4. ↵
    Jeong D, Dimsdale J. Sleep apnea and essential hypertension: a critical review of the epidemiological evidence for co-morbidity. Clin Exp Hypertens. 1989;A11:1301–1323.
  5. ↵
    Hudgel D. Treatment of obstructive sleep apnea: a review. Chest. 1996;109:1346–1358.
    OpenUrlCrossRefPubMed
  6. ↵
    Kellner C, Kirchheiner T, Ruhle KH. Continuous recording of systemic arterial pressure in patients with sleep apnea syndrome without and under nCPAP. Pneumologie. 1993;47:178–180.
  7. ↵
    Naughton MT, Rahman AM, Hara K, Floras JS, Bradley DT. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation. 1995;91:1725–1731.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Engleman HM, Gough K, Martin SE, Kingshott RN, Padfield PL, Douglas NJ. Ambulatory blood pressure on and off continuous positive airway pressure therapy for sleep apnea/hypopnea syndrome: effect in non-dippers. Sleep. 1996;19:378–381.
    OpenUrlPubMed
  9. ↵
    Guilleminault C, Stoohs R, Shiomi T, Kushida C, Schnittger I. Upper airway resistance syndrome, nocturnal blood pressure monitoring and borderline hypertension. Chest. 1996;109:901–908.
    OpenUrlCrossRefPubMed
  10. ↵
    Jennum P, Wldschiodtz G, Christensen NJ, Schwartz T. Blood pressure, catecholamines, and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nCPAP) treatment. Am J Hypertens. 1989;2:847–852.
    OpenUrlPubMed
  11. ↵
    Ali NJ, Davies RJ, Fleetham JA, Stradling JR. The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea. Chest. 1992;101:1526–1532.
    OpenUrlCrossRefPubMed
  12. ↵
    Suzuki M, Otsuka K, Guilleminault C. Long-term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. Sleep. 1993;16:545–549.
    OpenUrlPubMed
  13. ↵
    Mayer J, Backer H, Brandenburg U, Penzel T, Peter JH, Wichert PV. Blood pressure and sleep apnea: results of long-term nasal continuous positive airway pressure therapy. Cardiology. 1991;79:84–92.
    OpenUrlPubMed
  14. ↵
    Wilcox I, Grunstein RR, Hedner JA. Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. Sleep. 1993;16:539–544.
    OpenUrlPubMed
  15. ↵
    Worsno CJ, Pierce RJ, Naughton M. Systemic hypertension and obstructive sleep apnea. Sleep. 1993;6:S148–S149.
    OpenUrl
  16. ↵
    Davies RJO, Crosby J, Prothero A, Stradling JR. Ambulatory blood pressure and left ventricular hypertrophy in subjects with untreated obstructive sleep apnoea and snoring, compared with matched control subjects, and their response to treatment. Clin Sci. 1994;86:417–424.
    OpenUrlPubMed
  17. ↵
    Rauscher H, Formanek D, Popp W, Zwick H. Nasal CPAP and weight loss in hypertensive patients with obstructive apnoea. Thorax. 1993;48:529–533.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Akashiba T, Kurashina K, Minemura H, Yamamoto H, Horie T. Daytime hypertension and the effects of short-term nasal continuous positive airway pressure treatment in obstructive sleep apnea syndrome. Intern Med.. 1995;34:528–532.
    OpenUrlPubMed
  19. ↵
    Akashiba T, Minemura H, Horie T. The influence of nasal continuous positive airways pressure (CPAP) on nocturnal hypertension in obstructive sleep apnea (OSA) patients. Sleep. 1993;16(suppl 8):S35–S36.
  20. ↵
    Metropolitan Life Foundation. Metropolitan height and weight tables. Stat Bull Metrop Insur Co. 1983;64:1.
    OpenUrl
  21. ↵
    Hudgel D. Treatment of obstructive sleep apnea: a review. Chest. 1996;109:1346–1358.
  22. ↵
    Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens. 1995;8:311–315.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
January 2000, Volume 35, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Effect of Continuous Positive Airway Pressure on Blood Pressure
    Joel E. Dimsdale, Jose S. Loredo and Judi Profant
    Hypertension. 2000;35:144-147, originally published January 1, 2000
    https://doi.org/10.1161/01.HYP.35.1.144

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Effect of Continuous Positive Airway Pressure on Blood Pressure
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Effect of Continuous Positive Airway Pressure on Blood Pressure
    Joel E. Dimsdale, Jose S. Loredo and Judi Profant
    Hypertension. 2000;35:144-147, originally published January 1, 2000
    https://doi.org/10.1161/01.HYP.35.1.144
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
        • Pulmonary Hypertension
  • Quality and Outcomes
    • Ethics and Policy
  • Intervention, Surgery, Transplantation
    • Treatment
    • Behavioral/Psychosocial Treatment
  • Basic, Translational, and Clinical Research
    • Etiology
    • Autonomic Nervous System

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured